Ascelia Pharma AB (publ) (ST:ACE) — Market Cap & Net Worth
Market Cap & Net Worth: Ascelia Pharma AB (publ) (ACE)
Ascelia Pharma AB (publ) (ST:ACE) has a market capitalization of $8.55 Million (Skr79.42 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27545 globally and #602 in its home market, demonstrating a -2.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ascelia Pharma AB (publ)'s stock price Skr0.63 by its total outstanding shares 126868794 (126.87 Million). Also see Ascelia Pharma AB (publ) total assets for a full breakdown of the balance sheet.
Ascelia Pharma AB (publ) Market Cap History: 2019 to 2026
Ascelia Pharma AB (publ)'s market capitalization history from 2019 to 2026. Data shows change from $322.21 Million to $8.55 Million (-38.70% CAGR). Also see Ascelia Pharma AB (publ) cash flow conversion for how efficiently the company converts equity into cash flow.
Ascelia Pharma AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ascelia Pharma AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ascelia Pharma AB (publ) (ACE) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACE by Market Capitalization
Companies near Ascelia Pharma AB (publ) in the global market cap rankings as of September 19, 2026. Review Ascelia Pharma AB (publ) tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ascelia Pharma AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Ascelia Pharma AB (publ) Historical Marketcap From 2019 to 2026
Between 2019 and today, Ascelia Pharma AB (publ)'s market cap moved from $322.21 Million to $ 8.55 Million, with a yearly change of -38.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr8.55 Million | -80.53% |
| 2025 | Skr43.89 Million | +10.10% |
| 2024 | Skr39.87 Million | -13.35% |
| 2023 | Skr46.01 Million | -77.44% |
| 2022 | Skr203.98 Million | -49.95% |
| 2021 | Skr407.55 Million | -47.07% |
| 2020 | Skr770.04 Million | +138.98% |
| 2019 | Skr322.21 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Ascelia Pharma AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.55 Million USD |
| MoneyControl | $8.55 Million USD |
| MarketWatch | $8.55 Million USD |
| marketcap.company | $8.55 Million USD |
| Reuters | $8.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more